CureVac BV (CVAC) Stock Price Today
Key Stats
- $1.05BMarket Cap
- -Volume
- HealthSector
- $5.6052W High
- $2.5952W Low
- 34 DaysTypical Hold Time
- $599.28MEnterprise Value
- -Div Yield
- -Trading Activity
Track CureVac BV (CVAC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CureVac BV has traded between a low of $2.59 and a high of $5.6, highlighting its annual price range. Buy and sell CureVac BV shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CureVac BV
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Most Recent News
Goldilocks macro environment supports bullish market with strong USD and controlled inflation signals.
The current market is experiencing a Goldilocks macro environment characterized by a strong US dollar and controlled inflation, which supports a bullish outlook. Key factors include yield curve dynamics, where a re-steepening could boost gold, miners...
Dorian LPG boosts value by selling older ships, cutting debt, and ordering new dual-fuel vessels amid high freight rates.
Dorian LPG is capitalizing on record freight rates by selling older vessels, reducing debt, and ordering new Panamax dual-fuel ships designed to navigate canal congestion. These strategic moves improve earnings, strengthen the balance sheet, and allo...
One sizable IPO, one direct listing, and one SPAC debuted; Oura delays multibillion-dollar IPO.
This week saw the debut of one sizable IPO, one direct listing, and one SPAC, alongside initial filings from three small IPOs, one direct listing, and six SPACs. Notably, Oura postponed its planned multibillion-dollar IPO, marking a significant devel...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.